General
Preferred name
PRASUGREL
Synonyms
CS-747 ()
Prasugrel (Maleic acid) ()
PCR 4099 (Maleic acid) ()
PCR 4099 ()
LY640315 ()
Prasugrel (Effient) ()
Prasugrel (hydrochloride) ()
PRASUGREL HYDROCHLORIDE ()
PCR 4099 (hydrochloride) ()
Effient, Efient, Prasita,CS-747, LY640315,PCR 4099 ()
Prasugrel HCl, LY640315,PCR 4099 Hydrochloride ()
NSC-759625 ()
LY-640315 ()
Efient ()
Effient ()
Prasugrel HCl ()
Prasu doc ()
Prasugrel-d5 ()
P&D ID
PD009320
CAS
150322-43-3
389574-19-0
1127252-92-9
Tags
prodrug
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2009
Drug Status
approved
Drug indication
Acute coronary syndrome
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Prasugrel is a thienopyridine ADP receptor inhibitors which inhibits platelet aggregation by irreversibly binding to P2Y12 receptors.
METABOLISM
Prasugrel is not detected in plasma following oral administration. It is rapidly hydrolyzed in the intestine to thiolactone by human carboxylesterase (hCE) 2. This intermediate is further metabolized to its active metabolite, R-138727, in a single step by cytochrome P450 enzymes in the liver (primarily CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19). The active metabolite is further metabolized by S-methylation or cysteine conjugation to two inactive metabolites.; ; Unlike clopidogrel, transformation of prasugrel to its active metabolite does not appear to be affected by cytochrome P450 polymorphisms.
DESCRIPTION
This drug is metabolised to its active metabolite R-138727.
Marketed formulations may contain prasugrel hydrochloride (PubChem CID 10158453). (GtoPdb)
Marketed formulations may contain prasugrel hydrochloride (PubChem CID 10158453). (GtoPdb)
DESCRIPTION
Potent and selective GPR39 agonist; orally bioavailable
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
JUMP-Target 1 Compound Set
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
62
Molecular Weight
373.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
3.89
TPSA
46.61
Fraction CSP3
0.4
Chiral centers
1.0
Largest ring
6.0
QED
0.75
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
P2Y Receptor
P2Y
P2Y12
P2RY12
P2 Receptor
Pathway
GPCR/G protein
Neuroscience
Primary Target
Purinergic (P2Y) Receptors
MOA
Antagonist
Source data
